Targeting cellular senescence with fisetin for improving vascular endothelial function in older adults
Active Grant Awarded
- Award ID
- R01AG094826
- Recipient
-
The Regents Of The University Of Colorado UEI SPVKK1RC2MZ3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $809,971
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 4% complete
- Place of performance
- Boulder, CO 80309, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Institute on Aging, awarded The Regents of the University of Colorado, doing business as University of Colorado, $809,971 on September 9, 2026, under Grant R01AG094826 in the Aging Research program (CFDA 93.866). The full amount is obligated.
The award funds a project titled "Targeting Cellular Senescence with Fisetin for Improving Vascular Endothelial Function in Older Adults." The project uses fisetin, a natural flavonoid with senolytic effects that selectively removes senescent cells, to address endothelial dysfunction linked to aging. The project summary cites a prior small, short-term, randomized, placebo-controlled pilot trial in 41 older adults, which reported that intermittent fisetin treatment was safe and well tolerated. The period of performance runs from September 9, 2026 through August 31, 2031. Work is performed in Boulder, Colorado 80309, USA. The source names no sub-recipients.
The Aging Research program encourages biomedical, social, and behavioral research and research training on the aging process and the diseases and needs of people as they age.
Description
- Abstract
- Cardiovascular disease (CVD) is the leading cause of death in the united states and the majority of cvds occur in men and women ≥65 years of age. Vascular endothelial dysfunction, mediated by reduced bioavailability of nitric oxide (no) secondary to excess mitochondrial reactive oxygen species (MITOROS)- related oxidative stress, is a key mechanism of age-related increases in CVD risk. Cellular senescence is a state of largely permanent cell cycle arrest that drives endothelial dysfunction with aging at least in part by promoting excessive MITOROS. Excess cell senescence also changes the circulating milieu (i.e., blood) via the senescence-associated secretory phenotype (SASP) -- a collection of factors secreted by senescent cells that induces senescence in non-senescent cells and increases MITOROS. Establishing novel strategies targeting excess cell senescence to improve endothelial function in older adults is an urgent biomedical objective. Senolytics are compounds that selectively remove senescent cells. The natural flavonoid compound fisetin has senolytic effects in vivo. We have shown that oral intermittent fisetin treatment improves endothelial function in old mice by reducing cell senescence, which is linked to lower MITOROS-associated oxidative stress and changes in the circulating SASP milieu. We recently took the first step to translate our preclinical findings to humans in a small (N=41), short-term, randomized, placebo-controlled pilot clinical trial in older adults. Our results suggest that intermittent fisetin treatment is safe, well-tolerated and may improve endothelial function. Moreover, our preliminary mechanistic assessments indicate fisetin may reduce endothelial cell and circulating markers of cell senescence, reduce MITOROS-related inhibition of endothelial function and change the circulating SASP milieu to improve endothelial cell no bioavailability and MITOROS-related oxidative stress. We propose a properly powered, phase IIB, randomized, placebo-controlled, double-blind clinical trial as the critical next step to establish the efficacy of intermittent treatment with fisetin (6 X 3-day, 2 MG/KG/day dosing periods, 14 days apart) for improving endothelial function in men and women ≥65 years (N=108; 54/group). For mechanistic insight, we will assess the effects of fisetin on MITOROS-related inhibition of endothelial function as well as endothelial cell and circulating markers of cell senescence and the SASP. We will also assess if fisetin- evoked changes in the circulating SASP milieu enhance endothelial cell no production and decrease MITOROS bioactivity by suppressing cell senescence. Finaly, we will assess fisetin safety, tolerability and adherence. Hypothesis 1: intermittent fisetin treatment will improve endothelial function (primary outcome) in older adults. Hypothesis 2: fisetin will improve endothelial function in older adults by reducing MITOROS-related inhibition of endothelial function, which will be linked to reductions in cell senescence and the SASP. Fisetin will change the circulating SASP milieu to improve endothelial no production and MITOROS by reducing cell senescence. Hypothesis 3: intermittent fisetin treatment will be safe, well-tolerated and associated with high adherence.
Quick answers
Who received award R01AG094826?
R01AG094826 was awarded to The Regents Of The University Of Colorado by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R01AG094826 worth?
$809,971 has been obligated on R01AG094826.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award